ACM Deal Team:
Joel Adams (Director)
Precision Therapeutics (PTI) is committed to improving outcomes of cancer patients. Known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, PTI develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer. PTI's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician with the goal of optimizing patient outcomes.
Recent Precision Therapeutics News